Patent ID: 8822491

Claim:
A method of treating β-thalassemia or sickle cell anemia comprising: administering an effective amount of a pharmaceutical composition to a patient suffering from β-thalassemia, wherein the pharmaceutical composition comprising a compound of formula (I-a): or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 6a , and R 6b are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, heterocyclyl, aryl, —OR A , —OC(O)R A , —SR A , —N(R B ) 2 , —N(R A )C(O)R A , —C(O)N(R B ) 2 , —CN, —NO 2 , —C(O)R A , —C(O)OR A , —S(O)R A , —SO 2 R A —SO 2 N(R B ) 2 , and —NHSO 7 R B ; each instance of R 5 is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, heterocyclyl, aryl, —OR A , —OC(O)R A , —SR A , —N(R B ) 7 , —N(R A )C(O)R A , —C(O)N(R B ) 2 , —CN, —NO 2 , —C(O)R A , —C(O)OR A , —S(O)R A , —SO 2 R A —SO 2 N(R B ) 2 , and —NHSO 2 R B ; each R A is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, and aryl; each R B is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, and aryl, or two R B taken together with the intervening nitrogen form a heterocycle; n is 0, 1, 2, 3, or 4; and a pharmaceutically acceptable excipient.